Answers are grounded in this paper and cite their sources.
Background Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that may be complicated by Kasabach-Merritt phenomenon (KMP), a life-threatening consumptive coagulopathy syndrome. Although sirolimus has improved clinical outcomes, the optimal trough concentration during maintenance therapy after KMP remission remains unclear. This study aimed to evaluate the efficacy and safety associated with varying sirolimus exposure during the 12-month maintenance phase. Methods We retrospectively reviewed 26 patients with KHE who achieved KMP remission and received sirolimus maintenance therapy for at least 12 months. Patients were classified according to their average maintenance-phase sirolimus trough concentration into low exposure group (4∼8 ng/mL, n = 14) and high exposure group (8∼15 ng/mL, n = 12). Lesion regression, KMP recurrence, and treatment-related adverse events (AEs) were compared between groups. Multivariate Firth-corrected Logistic regression was applied for exploratory analysis of factors associated with KMP recurrence. To avoid reverse causation, only trough concentrations obtained prior to KMP recurrence were included in the regression models; measurements collected after recurrence were excluded. Results Baseline characteristics were comparable between the two groups. Both groups achieved progressive lesion regression during maintenance therapy. The high exposure group showed a significantly higher regression rate at 3 months; however, no significant differences were observed at 6 or 12-months follow-ups. In this small cohort, no statistically detectable difference in the frequency of sirolimus-related AEs was observed across exposure groups. Numerically, KMP recurrence was less common in the high exposure group (p = 0.036). In the exploratory multivariate analysis adjusting for clinical confounders, higher sirolimus exposure prior recurrence showed a protective trend against KMP recurrence but was not statistically significant (OR = 0.071, 95% CI = 0.003∼1.601, p = 0.096). Conclusion This exploratory analysis demonstrated that varying sirolimus exposure achieves comparable efficacy and safety within the 12 months maintenance phase among patients with KHE after KMP remission. High sirolimus exposure may accelerate early lesion regression and potentially reduce recurrence risk, although an independent protective benefit remains unconfirmed. Individualized sirolimus maintenance strategies guided by disease trajectory and therapeutic drug monitoring may be preferable to routine targeting of high trough concentrations.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: